Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Emerald Health: West Coast Cannabis Player With Biotech Focus

2018-02-05 seekingalpha
Our followers would have read our Weekly Cannabis Report in which we started tracking weekly performance of 11 cannabis companies, in addition to providing a weekly update on the latest news and developments in the sector. Starting today we are rolling out our initiating reports for the 11 names that we cover in order to offer deeper insights and analysis for our readers. (29-1)

Top-Performing Marijuana Stocks Of December

2017-12-28 seekingalpha
December has seen the culmination of at least 2 distinct catalysts propel several leading marijuana stocks much higher before the end of the year. (48-1)

Northern Vine Labs Combines the Best of Abattis and Emerald Health -- CFN Media

2017-11-22 marketwired
SEATTLE, WA--(Marketwired - Nov 22, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering the partnership between Abattis Bioceuticals Corp. (CSE: ATT) (CNSX: ATT) (CNSX: ATT.CN) (OTCQB: ATTBF) and Emerald Health Therapeutics Inc. (TSX VENTURE: EMH) (OTCQX: EMHTF) to run Northern Vine Laboratories as a joint venture, which promises to take advantage of a growing market for lab testing and extract products. (8-0)

CFN Media Exclusive CEO Interview: Abattis Validates Lab Strategy, Sets Stage for Rapid Growth

2017-11-06 marketwired
SEATTLE, WA--(Marketwired - Nov 6, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an exclusive executive interview with Rob Abenante, CEO of Abattis Bioceuticals Corp. (CSE: ATT) (CNSX: ATT) (CNSX: ATT.CN) (OTCQB: ATTBF). In the interview, Mr. Abenante discusses the company's cannabis testing and product development strategy in light of the recently announced partnership with Emerald Health Therapeutics. (27-0)

Emerald Health Expands Capabilities with Northern Vine Labs Deal -- CFN Media

2017-11-01 marketwired
SEATTLE, WA--(Marketwired - Nov 1, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering Emerald Health Therapeutics Inc.'s (TSX VENTURE: EMH) (OTCQX: EMHTF) recent deal with Abattis Bioceuticals Corp. to acquire a controlling interest in Northern Vine Labs. The agreement could grow Northern Vine into a thriving center for analytical testing, genetic research and development, tissue culture, and proprietary medicinal and therapeutic formulations. (8-1)

Abattis Offers a Solution to Canada's Cannabis Pesticide Problem -- CFN Media

2017-10-17 marketwired
SEATTLE, WA--(Marketwired - Oct 17, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing Abattis Bioceuticals Corp. (CSE: ATT) (CNSX: ATT) (CNSX: ATT.CN) (OTCQB: ATTBF), whose wholly-owned subsidiary is one of the only publicly-traded third-party cannabis testing laboratories. A steady stream of cannabis recalls has prompted regulators in Canada to call for the mandatory testing of cannabis for unauthorized pesticides. (4-0)

Abattis Prepares for Growth in Extracts -- CFN Media

2017-09-20 marketwired
SEATTLE, WA--(Marketwired - Sep 20, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing Abattis Bioceuticals Corp. (CSE: ATT) (ATT.CN) (CNSX: ATT) (OTCQB: ATTBF) and why its proprietary extraction technology represents an important breakthrough that shouldn't be ignored. While many licensed producers are focused on expanding capacity, the best opportunities may be those that can add value for existing licensed producers. (4-0)

It's Easy Being Green

2017-05-16 seekingalpha
Would you have done like everyone else and ignored it? Everyone did. There were no offers. None.

Abattis Announces the Official Launch of Northern Vine Laboratory

2017-05-03 accesswire
VANCOUVER, BC / ACCESSWIRE / May 3, 2017 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis") is pleased to announce that its subsidiary, Northern Vine Canada Inc. ("Northern Vine"), has officially launched its flagship laboratory, having completed its first successful test analysis.

Abattis Signs Exclusive Distribution Agreement for Proprietary Extraction Technology

2017-04-26 accesswire
VANCOUVER, BC / ACCESSWIRE / April 26, 2017 / Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") is pleased to announce that it has signed an exclusive distribution agreement, effective April 20, 2017 (the "Agreement"), with Suzhou Raybot Material Tech Corp. ("Raybot"). The Agreement allows Abattis to use Raybot's proprietary extraction technology and to exclusively sell the extraction equipment and services. (0-1)

Abattis Bioceuticals Announces New CEO

2017-04-10 accesswire
VANCOUVER, BC / ACCESSWIRE / April 10, 2017 / Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") is pleased to announce the appointment of Robert Abenante as President and Chief Executive Officer of the Company.

Abattis Bioceuticals Gets Added to the Marijuana Index by MJIC

2017-04-06 accesswire
VANCOUVER, BC / ACCESSWIRE / April 6, 2017 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), is pleased to announce it has officially been added to The Marijuana Index, within the Biotechnology sector.

Canada's Plans for Near-term Legalization Puts Testing into Focus -- CFN Media

2017-04-04 marketwired
SEATTLE, WA--(Marketwired - Apr 4, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article discussing the planned legalization of cannabis in Canada, the growing and urgent need for testing in both the existing and upcoming legal cannabis markets, and Abattis Bioceuticals Inc.'s (CSE: ATT) (OTCQB: ATTBF) role via the company's federally-licensed subsidiary, Northern Vine Labs.

Abattis: Legislation to Legalize Marijuana in Canada is Being Announced Next Month

2017-03-27 accesswire
VANCOUVER, BC / ACCESSWIRE / March 27, 2017 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis"), and its subsidiary, Northern Vine Labs, is anticipating the Liberal government's upcoming announcement, next month (the week of April 10th), on legislation that will legalize recreational marijuana use across Canada by July 1, 2018.

Abattis Welcomes Dr. David Galvez as Science Advisor to Northern Vine

2017-03-20 accesswire
VANCOUVER, BC / ACCESSWIRE / March 20, 2017 / Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT) (the "Company" or "Abattis") is pleased to announce that Dr. David Galvez, PhD, will be joining the team to lead Northern Vine's Science Advisory efforts.

CUSIP: 00258G103